Xspray Pharma AB (publ) has carried out a rights issue of units of approximately SEK 251 million. 

Xspray Pharma is a pharmaceutical company with numerous product candidates in clinical development, utilizing its innovative, patented HyNap-technology to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology segment often with high drug prices. The company's goal is to become a market leader of enhanced PKIs for cancer treatment. Xspray Pharma’s shares are traded at Nasdaq Stockholm.

Pareto Securities and Zonda Partners acted as Joint Bookrunners in the rights issue. Baker McKenzie acted as legal advisor to the Joint Bookrunners with a capital markets team consisting of Joakim Falkner and Johanna Flink.

Explore Our Newsroom